C4 Therapeutics
Develops targeted-protein degraders for oncology through TORPEDO.
$3.91
After-hours close+0.06 (+1.54%)
At close$3.85(−6.10%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 107.16%Insiders 2.70%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 110.57M · Float 83.71M · 75.7% free float
Institutions13F, as of Jun 30, 2026
158 holders · 118.49M shares · 54 new positions · 107 increased · 28 reduced · 26 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Morgan Stanley | 8.87M | 8.02% | −205.1K | Aug 13, 2026 |
| Ra Capital Management, L.P. | 8.00M | 7.24% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 7.90M | 7.14% | +5.85M | Aug 7, 2026 |
| LYNX1 Capital Management LP | 7.33M | 6.63% | +327.8K | Aug 13, 2026 |
| Squadron Capital Management LLC | 7.20M | 6.51% | +4.95M | Aug 14, 2026 |
| Bain Capital Life Sciences Investors, LLC | 7.17M | 6.49% | 0 | Aug 14, 2026 |
| JPMorgan Chase & Co | 4.75M | 4.29% | +1.52M | Aug 12, 2026 |
| Vanguard Capital Management LLC | 4.42M | 4.00% | +555.9K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Sirenia Capital Management LP | 9.90% | 23.51M | 13G | May 15, 2026 ↗ |
| RA Capital Management, L.P. | 9.90% | 9.44M | 13G | Oct 24, 2025 ↗ |
| Morgan Stanley | 9.30% | 8.97M | 13G | Feb 11, 2026 ↗ |
| Lynx1 Capital Management LP | 7.30% | 7.10M | 13G | Feb 17, 2026 ↗ |
| BlackRock, Inc. | 6.90% | 7.68M | 13G | Jul 27, 2026 ↗ |
| Soleus Private Equity Fund III, L.P. | 5.90% | 6.07M | 13G | Feb 12, 2026 ↗ |
| Squadron Master Fund LP | 5.00% | 5.55M | 13G | May 19, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Andrew Hirsch | director, officer: President & CEO | 1.07M | 0.97% | Feb 18, 2026 |
| Kendra Adams | officer: Chief Financial Officer | 385.1K | 0.35% | Feb 18, 2026 |
| Leonard Reyno | officer: Chief Medical Officer | 372.4K | 0.34% | Jul 13, 2026 |
| Paige Mahaney | officer: Chief Scientific Officer | 336.9K | 0.30% | Feb 18, 2026 |
| Kelly Schick | officer: Chief People Officer | 299.9K | 0.27% | Feb 18, 2026 |
| Scott N. Boyle | officer: Chief Business Officer | 298.8K | 0.27% | Feb 18, 2026 |
| Donna Roy Grogan | director | 74.9K | 0.07% | Jul 2, 2026 |
| Kenneth Carl Anderson | director | 72.0K | 0.07% | Jul 2, 2026 |
| Mark Mossler | officer: Chief Accounting Officer | 71.9K | 0.07% | Feb 18, 2026 |
12 people have not refiled in the last 18 months (606.7K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jan 16, 2026 | Leonard Reynoofficer: Chief Medical Officer | Sale | 10,000 | $2.22 | 156,382 |
CongressHouse and Senate disclosures
Not reported.